oligorecurrent

Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial

Ells Z, Meyer C, Kimura K, Wilhalme H, Cao M, Ludwig VB, Unterrainer LM, Sennung D, Nabong R, Felix C, Valle LF, Daley A, Czernin[...]

By afschroeder • April 3, 2026

LUNAR: a randomized phase 2 study of 177 Lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol)

Ma TM, Czernin J, Felix C, Alano R, Wilhalme H, Valle L, Steinberg ML, Dahlbom M, Reiter RE, Rettig MB, Cao M, Calais J, Kishan[...]

By sjmartinez • February 17, 2023